Want to see HK:1873 full AI Analyst Report?
Top Page
Viva Biotech Holdings
(1873)
Select Model
Select Model
Rating:60Neutral
Price Target:
HK$1.50
▼(-14.77% Downside)
Action:Reiterated
Date:08/28/26
The score is primarily supported by the return to profitability and an improving leverage profile. It is held back by persistent revenue contraction and weakened 2025 cash flow trends, while technicals are only moderately supportive and valuation appears reasonable based on the P/E.
Positive Factors
Profitability Recovery
The return to profitability, alongside stable gross and operating margins, indicates improved earnings quality after the 2022–2023 losses. Sustained margins could support cash generation and financial resilience if the company stabilizes its revenue base.
Negative Factors
Persistent Revenue Contraction
A multi-year decline in revenue weakens confidence in the durability of the CRO platform’s demand and limits operating leverage. Without renewed client activity or broader program wins, margin stability may not translate into sustained earnings growth.
Read all positive and negative factors
Positive Factors
Negative Factors
Profitability Recovery
The return to profitability, alongside stable gross and operating margins, indicates improved earnings quality after the 2022–2023 losses. Sustained margins could support cash generation and financial resilience if the company stabilizes its revenue base.
Read all positive factors
Viva Biotech Holdings (1873) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$2.66B
Dividend Yield0.27%
Average Volume (3M)5.78M
Price to Earnings (P/E)13.3
Beta (1Y)2.05
Revenue Growth7.38%
EPS Growth7.90%
CountryHK
Employees2,213
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)0.08
Shares Outstanding2,093,553,500
10 Day Avg. Volume2,928,400
30 Day Avg. Volume5,784,233
Financial Highlights & Ratios
PEG Ratio1.20
Price to Book (P/B)0.95
Price to Sales (P/S)2.19
P/FCF Ratio42.97
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.12
Revenue Forecast (FY)HK$2.13B
Viva Biotech Holdings Business Overview & Revenue Model
Company Description
Viva Biotech Holdings, founded in 2008 and based in Shanghai, China, operates as an investment holding company primarily dedicated to providing comprehensive, structure-based drug discovery services to biotechnology and pharmaceutical clients worl...
How the Company Makes Money
Viva Biotech primarily makes money by providing fee-for-service research and development work to external customers and recognizing revenue under service contracts. Key revenue streams include: (1) Contract research services: clients pay for outso...
Viva Biotech Holdings Financial Statement Overview
Summary
Income Statement
62
Positive
Balance Sheet
70
Positive
Cash Flow
48
Neutral
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.89B | 1.73B | 1.99B | 2.16B | 2.38B | 2.10B |
| Gross Profit | 653.15M | 655.56M | 687.40M | 738.43M | 815.68M | 650.98M |
| EBITDA | 382.33M | 385.38M | 428.00M | 391.01M | 436.35M | 369.94M |
| Net Income | 176.93M | 219.76M | 167.29M | -116.11M | -528.48M | 287.55M |
Balance Sheet | ||||||
| Total Assets | 6.89B | 7.20B | 7.05B | 7.45B | 7.92B | 8.04B |
| Cash, Cash Equivalents and Short-Term Investments | 1.06B | 1.13B | 941.58M | 1.04B | 678.57M | 800.95M |
| Total Debt | 897.96M | 1.33B | 1.28B | 1.90B | 2.82B | 2.65B |
| Total Liabilities | 2.92B | 3.19B | 3.23B | 3.76B | 4.32B | 4.13B |
| Stockholders Equity | 3.96B | 4.00B | 3.80B | 3.69B | 3.60B | 3.91B |
Cash Flow | ||||||
| Free Cash Flow | 284.60M | 88.02M | 182.32M | 195.57M | 136.72M | -487.35M |
| Operating Cash Flow | 427.35M | 206.04M | 373.99M | 383.40M | 386.05M | 77.83M |
| Investing Cash Flow | 46.96M | -93.76M | 185.90M | 439.17M | -372.80M | -868.84M |
| Financing Cash Flow | -356.38M | 36.61M | -657.76M | -429.50M | -143.20M | -653.16M |
Viva Biotech Holdings Technical Analysis
Negative
1.76
Price Trends
1.36
Negative
1.37
Negative
1.72
Negative
Market Momentum
-0.02
Positive
40.28
Neutral
20.43
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:1873, the sentiment is Negative. The current price of 1.76 is above the 20-day moving average (MA) of 1.42, above the 50-day MA of 1.36, and above the 200-day MA of 1.72, indicating a bearish trend. The MACD of -0.02 indicates Positive momentum. The RSI at 40.28 is Neutral, neither overbought nor oversold. The STOCH value of 20.43 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:1873.
Viva Biotech Holdings Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
74 Outperform | HK$195.33B | 33.16 | 10.51% | ― | 21.93% | 21.94% | |
68 Neutral | HK$67.37B | 56.60 | 5.86% | 1.11% | 16.62% | >-0.01% | |
66 Neutral | HK$24.93B | 56.35 | 15.79% | ― | 48.04% | 166.72% | |
62 Neutral | HK$70.85B | -13.82 | -16.23% | 0.35% | 53.48% | -120.02% | |
60 Neutral | HK$2.66B | 13.31 | 4.45% | 0.27% | 7.38% | 7.90% | |
59 Neutral | HK$78.10B | 41.53 | 10.96% | 0.83% | 20.39% | 26.48% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
HK:1873
Viva Biotech Holdings
1.28
-1.46
-53.28%
HK:1548
Genscript Biotech
32.36
15.31
89.79%
HK:2269
Wuxi Biologics (Cayman)
47.00
8.16
21.01%
HK:3759
Pharmaron Beijing Co., Ltd. Class H
27.54
1.95
7.62%
HK:2315
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H
56.10
30.56
119.66%
HK:6821
Asymchem Laboratories (Tianjin) Co., Ltd. Class H
134.20
33.69
33.52%
Viva Biotech Holdings Corporate Events
Viva Biotech grows revenue but faces profit margin squeeze in first half of 2026
Aug 26, 2026
Viva Biotech Holdings reported interim unaudited results for the six months ended June 30, 2026, showing revenue of RMB1,006.5 million, up from RMB831.9 million a year earlier, while gross profit was broadly flat at RMB341.7 million and gross marg...
Viva Biotech Sets Board Meeting to Approve Interim Results and Mull Dividend
Aug 14, 2026
Viva Biotech Holdings has scheduled a board meeting for August 26, 2026 to review and approve the interim financial results for the six months ended June 30, 2026. The board will also consider the possible declaration of an interim dividend, signa...
Viva Biotech Wins Strong Shareholder Backing at Annual General Meeting
Jun 26, 2026
Viva Biotech Holdings reported that all resolutions tabled at its annual general meeting on June 26, 2026, were approved by shareholders via poll. Investors backed the adoption of the 2025 financial statements, the re-election of key board members...
Viva Biotech Grants Performance-Linked RSUs to Core CDMO Staff
Jun 25, 2026
Viva Biotech Holdings has granted 6,224,000 restricted share units to 43 core employees in its CDMO operations under its existing RSU scheme, with each unit entitling the holder to one existing share upon vesting. The RSUs vest in three tranches b...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.